Crescent Biopharma to Present at September Investor Conferences
Crescent Biopharma (Nasdaq: CBIO), a biotechnology company focused on cancer therapies, has announced its participation in two major healthcare investor conferences in September 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Crescent Biopharma (Nasdaq: CBIO), a biotechnology company focused on cancer therapies, has announced its participation in two major healthcare investor conferences in September 2025.
The company will participate in a fireside chat at the Cantor Global Healthcare Conference on September 4, 2025, at 1:00 p.m. ET, and at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 5:35 p.m. ET. Both events will take place in New York.
Webcasts will be available on the company's investor relations website, with replays accessible for 90 days.
Details
News Market Reaction – CBIO
On Aug 28, the day this news came out, CBIO closed 0.70% below the previous close.
Data tracked by StockTitan Argus for the Aug 28 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in September:
- Cantor Global Healthcare Conference 2025, fireside chat on Thursday, September 4, 2025, at 1:00 p.m. ET in New York.
- Morgan Stanley 23rd Annual Global Healthcare Conference, fireside chat on Monday, September 8, 2025, at 5:35 p.m. ET in New York.
A live webcast of each presentation will be available in the Investors section of the Company's website at https://investors.crescentbiopharma.com/news-events/events, and a replay will be accessible for 90 days.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
Contact
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.